NASDAQ:PPBT

Purple Biotech Competitors

$3.97
+0.06 (+1.53 %)
(As of 05/7/2021 12:00 AM ET)
Add
Compare
Today's Range
$3.94
$4.09
50-Day Range
$3.83
$4.66
52-Week Range
$3.60
$14.40
Volume122,200 shs
Average Volume739,855 shs
Market Capitalization$69.52 million
P/E RatioN/A
Dividend YieldN/A
Beta2.33

Competitors

Purple Biotech (NASDAQ:PPBT) Vs. ONCT, CTXR, KMDA, ABUS, KZR, and TRVN

Should you be buying PPBT stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Purple Biotech, including Oncternal Therapeutics (ONCT), Citius Pharmaceuticals (CTXR), Kamada (KMDA), Arbutus Biopharma (ABUS), Kezar Life Sciences (KZR), and Trevena (TRVN).

Oncternal Therapeutics (NASDAQ:ONCT) and Purple Biotech (NASDAQ:PPBT) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, dividends, analyst recommendations, institutional ownership, risk and valuation.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Oncternal Therapeutics and Purple Biotech, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Oncternal Therapeutics00503.00
Purple Biotech00103.00

Oncternal Therapeutics currently has a consensus price target of $15.20, suggesting a potential upside of 173.38%. Given Purple Biotech's higher probable upside, analysts clearly believe Purple Biotech is more favorable than Oncternal Therapeutics.

Institutional & Insider Ownership

10.8% of Oncternal Therapeutics shares are held by institutional investors. Comparatively, 2.7% of Purple Biotech shares are held by institutional investors. 10.9% of Oncternal Therapeutics shares are held by insiders. Comparatively, 3.0% of Purple Biotech shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Oncternal Therapeutics and Purple Biotech's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oncternal Therapeutics$2.42 million113.41$-34,190,000.00($1.56)-3.56
Purple Biotech$1 million69.52$-5,850,000.00($3.00)-1.32

Purple Biotech has lower revenue, but higher earnings than Oncternal Therapeutics. Oncternal Therapeutics is trading at a lower price-to-earnings ratio than Purple Biotech, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Oncternal Therapeutics has a beta of 1.66, suggesting that its share price is 66% more volatile than the S&P 500. Comparatively, Purple Biotech has a beta of 2.33, suggesting that its share price is 133% more volatile than the S&P 500.

Profitability

This table compares Oncternal Therapeutics and Purple Biotech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Oncternal Therapeutics-746.10%-150.58%-91.87%
Purple BiotechN/AN/AN/A

Summary

Purple Biotech beats Oncternal Therapeutics on 7 of the 13 factors compared between the two stocks.

Purple Biotech (NASDAQ:PPBT) and Citius Pharmaceuticals (NASDAQ:CTXR) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, analyst recommendations, earnings and risk.

Profitability

This table compares Purple Biotech and Citius Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Purple BiotechN/AN/AN/A
Citius PharmaceuticalsN/A-62.67%-48.27%

Analyst Ratings

This is a summary of recent ratings and recommmendations for Purple Biotech and Citius Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Purple Biotech00103.00
Citius Pharmaceuticals00203.00

Citius Pharmaceuticals has a consensus target price of $5.00, suggesting a potential upside of 130.41%. Given Purple Biotech's higher probable upside, research analysts plainly believe Purple Biotech is more favorable than Citius Pharmaceuticals.

Risk and Volatility

Purple Biotech has a beta of 2.33, meaning that its share price is 133% more volatile than the S&P 500. Comparatively, Citius Pharmaceuticals has a beta of 1.48, meaning that its share price is 48% more volatile than the S&P 500.

Valuation and Earnings

This table compares Purple Biotech and Citius Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Purple Biotech$1 million69.52$-5,850,000.00($3.00)-1.32
Citius PharmaceuticalsN/AN/A$-17,550,000.00N/AN/A

Purple Biotech has higher revenue and earnings than Citius Pharmaceuticals.

Institutional & Insider Ownership

2.7% of Purple Biotech shares are held by institutional investors. Comparatively, 1.9% of Citius Pharmaceuticals shares are held by institutional investors. 3.0% of Purple Biotech shares are held by insiders. Comparatively, 33.9% of Citius Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Purple Biotech beats Citius Pharmaceuticals on 7 of the 9 factors compared between the two stocks.

Purple Biotech (NASDAQ:PPBT) and Kamada (NASDAQ:KMDA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, profitability, institutional ownership, risk, analyst recommendations and earnings.

Profitability

This table compares Purple Biotech and Kamada's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Purple BiotechN/AN/AN/A
Kamada15.60%12.89%10.66%

Analyst Recommendations

This is a summary of recent ratings for Purple Biotech and Kamada, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Purple Biotech00103.00
Kamada00203.00

Kamada has a consensus target price of $11.00, suggesting a potential upside of 79.74%. Given Purple Biotech's higher probable upside, equities analysts clearly believe Purple Biotech is more favorable than Kamada.

Risk and Volatility

Purple Biotech has a beta of 2.33, meaning that its stock price is 133% more volatile than the S&P 500. Comparatively, Kamada has a beta of 1.1, meaning that its stock price is 10% more volatile than the S&P 500.

Earnings & Valuation

This table compares Purple Biotech and Kamada's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Purple Biotech$1 million69.52$-5,850,000.00($3.00)-1.32
Kamada$127.19 million2.14$22.25 million$0.5511.13

Kamada has higher revenue and earnings than Purple Biotech. Purple Biotech is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

2.7% of Purple Biotech shares are owned by institutional investors. Comparatively, 14.3% of Kamada shares are owned by institutional investors. 3.0% of Purple Biotech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Kamada beats Purple Biotech on 9 of the 13 factors compared between the two stocks.

Purple Biotech (NASDAQ:PPBT) and Arbutus Biopharma (NASDAQ:ABUS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, profitability, institutional ownership, risk, analyst recommendations and earnings.

Profitability

This table compares Purple Biotech and Arbutus Biopharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Purple BiotechN/AN/AN/A
Arbutus Biopharma-1,163.48%N/A-59.66%

Institutional and Insider Ownership

2.7% of Purple Biotech shares are owned by institutional investors. Comparatively, 28.4% of Arbutus Biopharma shares are owned by institutional investors. 3.0% of Purple Biotech shares are owned by company insiders. Comparatively, 6.7% of Arbutus Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Risk and Volatility

Purple Biotech has a beta of 2.33, meaning that its stock price is 133% more volatile than the S&P 500. Comparatively, Arbutus Biopharma has a beta of 3.15, meaning that its stock price is 215% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings for Purple Biotech and Arbutus Biopharma, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Purple Biotech00103.00
Arbutus Biopharma02502.71

Arbutus Biopharma has a consensus target price of $6.50, suggesting a potential upside of 131.32%. Given Purple Biotech's stronger consensus rating and higher probable upside, equities analysts clearly believe Purple Biotech is more favorable than Arbutus Biopharma.

Earnings & Valuation

This table compares Purple Biotech and Arbutus Biopharma's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Purple Biotech$1 million69.52$-5,850,000.00($3.00)-1.32
Arbutus Biopharma$6.01 million45.07$-153,720,000.00($1.62)-1.73

Purple Biotech has higher earnings, but lower revenue than Arbutus Biopharma. Arbutus Biopharma is trading at a lower price-to-earnings ratio than Purple Biotech, indicating that it is currently the more affordable of the two stocks.

Summary

Purple Biotech beats Arbutus Biopharma on 7 of the 13 factors compared between the two stocks.

Purple Biotech (NASDAQ:PPBT) and Kezar Life Sciences (NASDAQ:KZR) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations and earnings.

Profitability

This table compares Purple Biotech and Kezar Life Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Purple BiotechN/AN/AN/A
Kezar Life SciencesN/A-31.71%-29.17%

Institutional & Insider Ownership

2.7% of Purple Biotech shares are owned by institutional investors. Comparatively, 49.5% of Kezar Life Sciences shares are owned by institutional investors. 3.0% of Purple Biotech shares are owned by company insiders. Comparatively, 7.6% of Kezar Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Volatility and Risk

Purple Biotech has a beta of 2.33, meaning that its share price is 133% more volatile than the S&P 500. Comparatively, Kezar Life Sciences has a beta of 0.33, meaning that its share price is 67% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Purple Biotech and Kezar Life Sciences, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Purple Biotech00103.00
Kezar Life Sciences01202.67

Kezar Life Sciences has a consensus target price of $15.00, suggesting a potential upside of 167.86%. Given Purple Biotech's stronger consensus rating and higher probable upside, equities research analysts clearly believe Purple Biotech is more favorable than Kezar Life Sciences.

Earnings and Valuation

This table compares Purple Biotech and Kezar Life Sciences' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Purple Biotech$1 million69.52$-5,850,000.00($3.00)-1.32
Kezar Life SciencesN/AN/A$-35,090,000.00($1.84)-3.04

Purple Biotech has higher revenue and earnings than Kezar Life Sciences. Kezar Life Sciences is trading at a lower price-to-earnings ratio than Purple Biotech, indicating that it is currently the more affordable of the two stocks.

Summary

Purple Biotech beats Kezar Life Sciences on 8 of the 12 factors compared between the two stocks.

Purple Biotech (NASDAQ:PPBT) and Trevena (NASDAQ:TRVN) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations and earnings.

Profitability

This table compares Purple Biotech and Trevena's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Purple BiotechN/AN/AN/A
TrevenaN/A-42.49%-34.83%

Earnings and Valuation

This table compares Purple Biotech and Trevena's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Purple Biotech$1 million69.52$-5,850,000.00($3.00)-1.32
Trevena$30,000.008,762.55$-24,870,000.00($0.27)-6.04

Purple Biotech has higher revenue and earnings than Trevena. Trevena is trading at a lower price-to-earnings ratio than Purple Biotech, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

2.7% of Purple Biotech shares are owned by institutional investors. Comparatively, 11.6% of Trevena shares are owned by institutional investors. 3.0% of Purple Biotech shares are owned by company insiders. Comparatively, 5.2% of Trevena shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Purple Biotech and Trevena, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Purple Biotech00103.00
Trevena01302.75

Trevena has a consensus target price of $5.00, suggesting a potential upside of 206.75%. Given Purple Biotech's stronger consensus rating and higher probable upside, equities research analysts clearly believe Purple Biotech is more favorable than Trevena.

Volatility and Risk

Purple Biotech has a beta of 2.33, meaning that its share price is 133% more volatile than the S&P 500. Comparatively, Trevena has a beta of 2.59, meaning that its share price is 159% more volatile than the S&P 500.

Summary

Purple Biotech beats Trevena on 7 of the 13 factors compared between the two stocks.


Purple Biotech Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Oncternal Therapeutics logo
ONCT
Oncternal Therapeutics
1.7$5.56+2.0%$274.46 million$2.42 million-4.88Earnings Announcement
Citius Pharmaceuticals logo
CTXR
Citius Pharmaceuticals
1.3$2.17+0.5%$272.95 millionN/A0.00Upcoming Earnings
Kamada logo
KMDA
Kamada
1.4$6.12+0.7%$272.46 million$127.19 million12.75Upcoming Earnings
Arbutus Biopharma logo
ABUS
Arbutus Biopharma
1.4$2.81+0.4%$270.70 million$6.01 million-2.28Earnings Announcement
Kezar Life Sciences logo
KZR
Kezar Life Sciences
1.3$5.60+1.8%$269.25 millionN/A-4.48High Trading Volume
Trevena logo
TRVN
Trevena
1.3$1.63+0.0%$262.88 million$30,000.00-7.09Earnings Announcement
Mustang Bio logo
MBIO
Mustang Bio
1.6$3.05+3.6%$259.78 millionN/A-2.44Gap Up
Cerecor logo
CERC
Cerecor
1.8$2.72+1.5%$259.64 million$6.75 million-9.07Upcoming Earnings
9 Meters Biopharma logo
NMTR
9 Meters Biopharma
1.8$1.17+0.0%$252.80 millionN/A0.00
TFF Pharmaceuticals logo
TFFP
TFF Pharmaceuticals
1.4$9.59+2.8%$243.24 millionN/A-3.63Upcoming Earnings
Sierra Oncology logo
SRRA
Sierra Oncology
1.8$19.17+3.2%$236.75 millionN/A-1.37
PLx Pharma logo
PLXP
PLx Pharma
1.5$10.34+4.8%$236.17 million$570,000.00-8.41Upcoming Earnings
Ovid Therapeutics logo
OVID
Ovid Therapeutics
1.5$3.48+0.6%$235.91 millionN/A-2.47
Immunome logo
IMNM
Immunome
1.0$21.98+2.4%$234.31 millionN/A0.00
Chiasma logo
CHMA
Chiasma
1.6$4.03+1.2%$233.11 millionN/A-2.78Earnings Announcement
Analyst Downgrade
Analyst Revision
Galectin Therapeutics logo
GALT
Galectin Therapeutics
1.4$4.00+8.0%$228.62 millionN/A-10.26
Mereo BioPharma Group logo
MREO
Mereo BioPharma Group
1.5$3.37+2.1%$228.46 millionN/A-1.35
Immutep logo
IMMP
Immutep
1.3$3.52+9.1%$228.35 million$4.92 million0.00Gap Up
TLC
Taiwan Liposome
1.2$5.39+2.0%$226.80 million$6.99 million-6.74Upcoming Earnings
Analyst Revision
AVEO Pharmaceuticals logo
AVEO
AVEO Pharmaceuticals
1.2$6.43+3.1%$220.94 million$28.80 million-4.15
NextCure logo
NXTC
NextCure
1.6$7.95+1.1%$219.50 million$6.35 million-7.04Earnings Announcement
Neptune Wellness Solutions logo
NEPT
Neptune Wellness Solutions
1.3$1.31+1.5%$216.87 million$22.05 million-2.62
BioVie logo
BIVI
BioVie
1.2$15.35+14.0%$213.61 millionN/A0.00Gap Up
Adamas Pharmaceuticals logo
ADMS
Adamas Pharmaceuticals
1.7$5.15+2.5%$213.04 million$54.64 million-2.33
Larimar Therapeutics logo
LRMR
Larimar Therapeutics
1.5$13.86+1.4%$213 millionN/A-2.60
Harrow Health logo
HROW
Harrow Health
1.4$8.17+0.7%$212.29 million$51.17 million-102.13Upcoming Earnings
Kindred Biosciences logo
KIN
Kindred Biosciences
1.6$4.63+0.2%$209.62 million$4.26 million-6.71Upcoming Earnings
CTI BioPharma logo
CTIC
CTI BioPharma
1.7$2.25+1.3%$209.59 million$3.35 million-3.31High Trading Volume
Corbus Pharmaceuticals logo
CRBP
Corbus Pharmaceuticals
1.7$1.65+6.7%$206.30 million$36.14 million-0.92
Tricida logo
TCDA
Tricida
1.9$4.06+2.7%$204.11 millionN/A-0.76Earnings Announcement
Orphazyme A/S logo
ORPH
Orphazyme A/S
1.0$5.75+48.9%$200.97 millionN/A0.00High Trading Volume
Gap Down
MediciNova logo
MNOV
MediciNova
1.2$4.10+2.4%$199.95 millionN/A0.00Upcoming Earnings
vTv Therapeutics logo
VTVT
vTv Therapeutics
1.2$2.47+3.6%$199.24 million$2.76 million-5.61Analyst Downgrade
Medicenna Therapeutics logo
MDNA
Medicenna Therapeutics
0.7$3.69+4.9%$197.59 millionN/A-18.45High Trading Volume
Gap Up
Sol-Gel Technologies logo
SLGL
Sol-Gel Technologies
1.2$9.54+1.0%$194.52 million$22.90 million-7.17Upcoming Earnings
Xeris Pharmaceuticals logo
XERS
Xeris Pharmaceuticals
1.6$3.25+4.3%$194.24 million$2.72 million-0.82Upcoming Earnings
Eton Pharmaceuticals logo
ETON
Eton Pharmaceuticals
1.3$7.91+2.3%$193.66 million$460,000.00-6.65Upcoming Earnings
Iterum Therapeutics logo
ITRM
Iterum Therapeutics
1.3$1.07+3.7%$191.68 million$40,000.00-0.26Upcoming Earnings
Checkpoint Therapeutics logo
CKPT
Checkpoint Therapeutics
1.2$2.51+6.0%$188.78 million$1.71 million-5.46Earnings Announcement
Analyst Revision
Gap Up
VYNE Therapeutics logo
VYNE
VYNE Therapeutics
1.5$3.63+1.9%$186.54 million$10.64 million-0.97Earnings Announcement
Analyst Report
Insider Selling
Analyst Revision
Gap Up
Marker Therapeutics logo
MRKR
Marker Therapeutics
1.5$2.35+0.4%$186.36 million$210,000.00-4.27Upcoming Earnings
Analyst Revision
Zynerba Pharmaceuticals logo
ZYNE
Zynerba Pharmaceuticals
1.3$4.49+10.7%$185.22 million$90,000.00-2.43Analyst Revision
Novan logo
NOVN
Novan
1.6$1.22+6.6%$185.02 million$4.90 million-5.55
Lannett logo
LCI
Lannett
2.0$4.43+0.5%$183.41 million$545.74 million-6.15Earnings Announcement
Osmotica Pharmaceuticals logo
OSMT
Osmotica Pharmaceuticals
1.1$2.91+2.1%$182.12 million$240.03 million-3.16Upcoming Earnings
IMV logo
IMV
IMV
0.8$2.66+1.9%$180.11 million$430,000.00-5.78Upcoming Earnings
Equillium logo
EQ
Equillium
1.9$6.03+1.2%$175.11 millionN/A-3.84Upcoming Earnings
Lantern Pharma logo
LTRN
Lantern Pharma
1.2$15.62+8.5%$174.65 millionN/A0.00Analyst Revision
Gap Up
Enochian Biosciences logo
ENOB
Enochian Biosciences
0.3$3.63+4.1%$173.38 millionN/A0.00Gap Up
NuCana logo
NCNA
NuCana
1.5$3.57+3.9%$173.13 millionN/A-3.53Gap Up
This page was last updated on 5/10/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.